BriaCell Therapeutics annual return on equity
2021
2022
2023
2025
BriaCell Therapeutics Return on Equity (ROE) Growth & History (BCTX)
BriaCell Therapeutics's return on equity was −359.23% for fiscal 2025.
View full BriaCell Therapeutics company overviewBriaCell Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-07-31 | −359.23% | — |
| 2023 | 2023-07-31 | −619.75% | −478.50 pp |
| 2022 | 2022-07-31 | −141.25% | −30.42 pp |
| 2021 | 2021-07-31 | −110.84% | — |
BriaCell Therapeutics quarterly return on equity
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-04-30 | −26.72% | +54.07 pp |
| Q2 2026 | 2026-01-31 | −36.51% | +144.80 pp |
| Q1 2026 | 2025-10-31 | −61.44% | +1067.30 pp |
| Q4 2025 | 2025-07-31 | −55.28% | — |
| Q3 2025 | 2025-04-30 | −80.79% | — |
| Q2 2025 | 2025-01-31 | −181.31% | — |
| Q1 2025 | 2024-10-31 | −1,128.74% | — |
| Q2 2023 | 2023-01-31 | −262.47% | −313.09 pp |
| Q1 2023 | 2022-10-31 | −10.71% | — |
| Q4 2022 | 2022-07-31 | −4.44% | — |
| Q3 2022 | 2022-04-30 | −75.92% | — |
| Q2 2022 | 2022-01-31 | 50.62% | — |
BriaCell Therapeutics return on equity trends
Between the periods ended 2021-07-31 and 2025-07-31, BriaCell Therapeutics's return on equity decreased from −110.84% to −359.23%, a change of −248.39 percentage points. The latest reported quarter, Q3 2026, shows −26.72%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BriaCell Therapeutics source filings ↗